From Cystic Lung Lesions to Pulmonary Lymphangioleiomyomatosis: A Case-Based Diagnostic and Therapeutic Approach.

Mohsen Sadeghi, Fatemeh Sadat Hosseini Khajouei, Amir Morteza Soleimani

Abstract readCase Reports

In one paragraph

Article in Tanaffos, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mohsen SadeghiChronic Respiratory Diseases Research Center (CRDRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Fatemeh Sadat Hosseini KhajoueiStudent Research Committee, Arak University of Medical Sciences, Arak, Iran.

Amir Morteza SoleimaniDepartment of Internal Medicine, School of Medicine, Arak University of Medical Sciences, Arak, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Lymphangioleiomyomatosis (LAM) is a rare, progressive cystic lung disease that primarily affects women of reproductive age. It arises from abnormal proliferation of smooth muscle-like cells, resulting in cystic lung remodeling, impaired airflow, and recurrent pneumothorax. Serum vascular endothelial growth factor D (VEGF-D) can support diagnosis, but normal levels do not exclude the disease. Case Presentation: We describe a 37-year-old woman with six months of progressive dyspnea and hypoxia (SaO Conclusion: This case shows that normal VEGF-D levels do not rule out LAM. Histopathologic confirmation remains essential when clinical and imaging findings are suggestive. Timely diagnosis enables initiation of mTOR inhibitor therapy, which can help stabilize lung function, manage cystic lesions, and inform decisions about further interventions, including lung transplantation.

Indexed as

Cystic lung lesionLAMLung lymphangioleiomyomatosisPEComaSerum vascular endothelial growth factor D

Identifiers

PMID42757378

PMCPMC13585209

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.